Monopar Therapeutics shares technical analysis: Bearish signals persist with eyes on $65.17 support
Monopar Therapeutics (MNPR) stock is trading at $69.37, down 3.39% on the day and holding near session lows. The stock is currently below its key moving averages.
71.3350
79.4350
Highlights
- MNPR/USD trades below all key moving averages on hourly and daily charts, confirming short-, medium-, and long-term bearish trend.
- Momentum and oscillators including MACD, ADX, and RSI point to sustained selling pressure, with most signals showing oversold conditions intraday.
- The projected trading range for the next 2 to 3 sessions is $65.1679 to $73.5621, with a high probability of further declines if support breaks.
Bearish momentum prevails as strong selling meets technical barriers
MNPR/USD trades below the MA-20 ($71.40) and MA-50 ($75.97) on the hourly chart, and remains under the MA-200 ($76.85) on the daily timeframe. The immediate resistance is marked by the Ichimoku Kijun at $72.78, which may limit near-term rebounds. Momentum indicators reinforce the bearish setup: MACD signals Strong Sell, ADX is in Sell mode, and RSI stands at 35.27 (Sell). Both CCI and Bull/Bear Power are oversold, highlighting strong seller activity, while Stoch RSI and Awesome Oscillator remain neutral.
Downside favored as range-bound outlook limits rebound potential
In the next 2–3 trading days, MNPR is expected to trade within the $65.17 to $73.56 volatility band relative to current levels. The probability of an upswing is very low, with downside continuation highly likely. The baseline scenario is for price to consolidate sideways between nearby support and resistance. If price rises above $72.78, a move towards the upper end of the projected range is possible, but if it drops below $65.17, further selling could drive the stock to new lows.
Earlier, analysts noted that Monopar Therapeutics stock was experiencing persistent bearish momentum and elevated downside risk. This latest technical setup reinforces the bearish outlook, with traders advised to monitor the $65.17 support level closely as a break below it could trigger accelerated selling.
Latest Monopar Therapeutics News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
